Anterior uveitis is an inflammation of the uveal tract (middle layer of the eye), which includes the iris (colored part of the eye) and adjacent tissue, known as the ciliary body. If untreated or insufficiently treated, it can lead to severe complications including the development of glaucoma, cataract or retinal edema, often resulting in permanent damage including loss of vision.
In most cases of anterior uveitis, there is no obvious underlying cause, as the condition can occur as a result of a variety of factors including trauma to the eye, complications of other ocular conditions or autoimmune disease. Anterior uveitis often occurs for no apparent reason as the result of the immune system malfunctioning and triggering the process of inflammation even though no infection is present. Such inflammation without an infection is known as non-infectious anterior uveitis.
Signs/symptoms may include redness, soreness and inflammation of the eye, blurring of vision, sensitivity to light and a small pupil.
An estimated 17.6% of active uveitis patients experience transient or permanent vision loss on an annual basis. Uveitis is responsible for more than 2.8% of cases of blindness in the U.S., making it an important cause of vision loss and impairment. Incidence in the U.S. ranges from approximately 26.6 – 102 per 100,000 adults annually. While it occurs in all age groups, the highest incidence of the disease is in those over age 65.
For additional information on our clinical study of EGP-437 to treat non-infectious anterior uveitis, please click here.